Monoclonal antibody prevents malaria infection in African adults
A monoclonal antibody, CIS43LS, was found up to 88.2% effective in preventing malaria in African adults during a six-month malaria season, offering a new tool for malaria prevention in endemic regions. The NIH-sponsored trial highlights the potential for monoclonal antibodies to complement existing malaria interventions.
Related Clinical Trials
Reference News
Monoclonal antibody prevents malaria infection in African adults
A monoclonal antibody, CIS43LS, was found up to 88.2% effective in preventing malaria in African adults during a six-month malaria season, offering a new tool for malaria prevention in endemic regions. The NIH-sponsored trial highlights the potential for monoclonal antibodies to complement existing malaria interventions.